Li D, Darden C, Osman N, Sayeed S, Jackson L, Garbinsky D, Chauhan A. Real-world clinical and patient-reported outcomes from the longitudinal telotristat ethyl treatment registry of patients with neuroendocrine tumors. Cancer Manag Res. 2022 Oct 17;14:3009-20. doi: 10.2147/CMAR.S386419
Hofheinz RD, Bruix J, Demetri GD, Grothey A, Marian M, Bartsch J, Odom D. Effect of regorafenib in delaying definitive deterioration in health-related quality of life in patients with advanced cancer of three different tumor types. Cancer Manag Res. 2021 Jul 12;13:5523-33. doi: 10.2147/CMAR.S305939
Stuckey HL, Oser SM, Miller EL, Oser TK, Peyrot M, Sharma A. “Not today, diabetes”: using blog analysis to understand emotional interactions and support among people with type 1 diabetes. Front Clin Diabetes Healthc. 2021 Jan 6;1:613569. doi: 10.3389/fcdhc.2020.613569
Cuyún Carter G, Barrett AM, Kaye JA, Liepa AM, Winfree KB, John WJ. A comprehensive review of nongenetic prognostic and predictive factors influencing the heterogeneity of outcomes in advanced non-small-cell lung cancer. Cancer Manag Res. 2014 Oct 23;2014(6):437-49. doi: 10.2147/CMAR.S63603
Patel RI, Davis PJ, Orr RJ, Ferrari LR, Rimar S, Hannallah RS, Cohen IT, Colingo K, Donlon JV, Haberkern CM, McGowan FX, Prillaman BA, Parasuraman TV, Creed MR. Single-dose ondansetron prevents postoperative vomiting in pediatric outpatients. Anesth Analg. 1997 Sep;85(3):538-45. doi: 10.1097/00000539-199709000-00011
Gratz I, Allen E, Afshar M, Joslyn AF, Buxbaum J, Prillaman B. The effects of the menstrual cycle on the incidence of postoperative nausea and vomiting (PONV) and efficacy of ondansetron. Anesth Analg. 1996 Sep;83(3):565-9. doi: 10.1097/00000539-199609000-00022